To Get more Insights,  Request A Free Sample 

Unlocking New Avenues for Growth in the Shingles Vaccine Market

Two major trends are creating significant growth opportunities in the shingles vaccine market. 

• Strategic development of combination vaccines designed to improve patient convenience and increase vaccination rates

Companies are actively pursuing formulations that co-administer the shingles vaccine with other routine adult immunizations like those for influenza, RSV, and COVID-19. A recent clinical trial concluded that adjuvanted influenza and shingles vaccines can be safely administered at the same time. This move toward combination shots addresses "vaccine fatigue" and streamlines the immunization process, making it a compelling value proposition for both patients and healthcare providers.

• Expansion of vaccine recommendations to include younger, high-risk populations

Regulatory bodies like the U.S. CDC now recommend the shingles vaccine for immunocompromised adults aged 19 and older, a significant shift from the previous 50-and-over guidance for the general population. Conditions like leukemia, lymphoma, or undergoing chemotherapy place these younger adults at a much higher risk for severe shingles cases. This policy evolution unlocks a substantial and previously untapped patient demographic, creating a new and medically necessary demand channel for vaccine manufacturers to serve.

National Immunization Programs Fueling Widespread Shingles Vaccine Market Demand

Public health initiatives are dramatically shaping the demand curve for the global shingles vaccine market. In Australia, the inclusion of Shingrix in the National Immunisation Program (NIP) led to approximately 1.25 million doses being administered in the first six months of the program ending April 30, 2024. The uptake was rapid, increasing from 11,019 monthly doses in October 2023 to 269,029 by April 2024. A surge in Australia is mirrored by similar government-backed programs globally. In Spain's Andalusia region, 27,596 people were vaccinated against shingles in the six months following May 2024.

These programs are expanding access and driving significant volume. The UK's NHS is actively managing its Shingrix program for those turning 65 and 70. In Japan, the government will add shingles vaccines to its national immunization program starting in April 2025, initially targeting individuals aged 65. The program includes a five-year transitional measure for older age groups. In Canada, Ontario's publicly funded program extended eligibility through December 31, 2024, for those who missed vaccination opportunities due to the pandemic. Similarly, the US Inflation Reduction Act, which eliminated out-of-pocket costs for Medicare Part D beneficiaries, was associated with a substantial increase in shingles vaccinations. Between January 2022 and December 2023, 8.3 million doses were dispensed to individuals with Part D coverage.

Expanding Recommendations for At-Risk Groups Redefines the Shingles Vaccine Market

A pivotal driver of demand is the formal expansion of vaccine recommendations to younger, immunocompromised adults. The U.S. CDC now recommends the shingles vaccine for adults aged 19 and older with weakened immune systems. A policy shift acknowledges the heightened risk in this demographic. Following this guidance, NHS England announced that starting in September 2025, around 300,000 more severely immunosuppressed adults aged 18 to 49 will become eligible for vaccination. A change reflects expert advice recognizing similar hospitalization risks in younger at-risk adults compared to older cohorts.

This growing focus is stimulating targeted research and increasing vaccine administration in specialized patient groups. In Australia, the NIP now provides free access to Shingrix for eligible immunocompromised individuals 18 years and over. Specific data from New South Wales shows 384,208 Shingrix doses were given to adults over 18 between November 2023 and April 2024. Safety surveillance is also adapting; between December 2022 and August 2024, New Zealand's pharmacovigilance database received 296 case reports for Shingrix, with 106 classified as serious. The VAERS database in the U.S. received 66,849 reports for the vaccine between late 2017 and April 2024, with 1,830 classified as serious. A 2025 study further validated vaccine effectiveness in immunocompromised patients with inflammatory arthritis.

Segmental Analysis 

Shingrix's Market Supremacy Fueled by Unprecedented Efficacy and Longevity

Shingrix's commanding 95% share of the shingles vaccine market is a direct result of its superior product profile, which offers exceptionally high and durable protection against the virus. This recombinant, adjuvanted vaccine has demonstrated vaccine efficacy of up to 97% in adults aged 50 and older, a figure that remains robust even in the oldest age groups. A key market differentiator is its sustained effectiveness; recent 2024 data from a long-term follow-up trial, which monitored over 7,000 participants, confirmed that Shingrix maintains up to 79.7% efficacy for more than a decade (from year six to year 11) after the initial two-dose course. This longevity far surpasses that of its predecessor, the live-attenuated Zostavax, which showed significantly waning protection from around five years post-vaccination.

The vaccine's robust performance in pivotal trials, such as ZOE-50 which included over 14,750 patients, has cemented its status as the preferred choice among healthcare providers. Its cost-effectiveness, with incremental cost-effectiveness ratios (ICERs) ranging from $10,000 to $47,000 per quality-adjusted life year (QALY) gained, further solidifies its position in the shingles vaccine market. The U.S. Centers for Disease Control and Prevention (CDC) preferentially recommends Shingrix for all adults aged 50 and over, including those who previously received Zostavax, contributing significantly to its widespread adoption.

• Pivotal Clinical Trials: The ZOE-50 and ZOE-70 phase III trials, which collectively enrolled more than 29,300 subjects, established the vaccine's foundational efficacy and safety data.
• Decade-Long Protection: A 2024 long-term follow-up study (ZOSTER-049) involving over 7,000 participants demonstrated that vaccine efficacy remains high for approximately 11 years after initial vaccination.
• Global Regulatory Approval: Shingrix is licensed in over 40 countries worldwide, reflecting broad international consensus on its clinical benefits and safety.

Recombinant Technology Revolutionizes the Shingles Vaccine Market Landscape

Recombinant vaccines hold an overwhelming 96% of the shingles vaccine market due to their advanced design, which yields a safer and more effective product compared to older live attenuated vaccines. Unlike live vaccines that use a weakened virus, recombinant vaccines like Shingrix use a specific, non-infectious piece of the virus—the glycoprotein E (gE) antigen—combined with an adjuvant system, AS01B, to stimulate a strong and targeted immune response. This method is particularly crucial for the target demographic of older adults, whose immune systems naturally decline with age. Each 0.5 mL dose is precisely formulated with 50 micrograms of the gE antigen and 50 micrograms each of the two components in the AS01B adjuvant to optimize this response.

The non-live nature of recombinant vaccines is a critical market advantage, as it allows them to be safely administered to a broader patient population, including immunocompromised adults aged 18 and over, for whom live vaccines are often contraindicated. This expanded eligibility significantly increases the potential patient pool. The vaccine's persistent immunity, which is anticipated to last for up to 15 years post-vaccination, eliminates the need for frequent boosters and provides long-term peace of mind for patients and providers, making it the heavily deployed and preferred option in the shingles vaccine market.

• Enhanced Immune Response: The proprietary AS01B adjuvant system contains 50 micrograms of QS-21 and 50 micrograms of MPL, which work together to boost the body's cellular and humoral response to the gE antigen.
• Safety for Immunocompromised: Being a non-live vaccine, it is recommended for adults aged 18 and older who are or will be at increased risk of shingles due to immunodeficiency.
• Superior Prevention: Studies have shown recombinant vaccines are significantly more efficacious in preventing shingles and its debilitating complication, postherpetic neuralgia (PHN), than the live attenuated vaccine.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America's Unwavering Command of the Global Shingles Vaccine Market

North America commands the shingles vaccine market with over 65% market share, a position fortified by robust public health infrastructure and significant corporate investment. In the first half of 2024, GSK reported Shingrix sales of £859 million in the U.S. alone. To meet sustained demand, GSK is investing up to $800 million to expand its manufacturing site in Marietta, Pennsylvania, a project expected to create over 200 new jobs. The state of Pennsylvania is contributing with a $1.2 million funding proposal for the project. Vaccine accessibility is also a key factor; as of January 2024, the U.S. list price for a full two-dose course of Shingrix was $395.80.

The market is also defined by a strong R&D pipeline. Pfizer's Phase 1/2 trial for its mRNA shingles vaccine, conducted primarily in the U.S., aims to enroll up to 900 healthy volunteers. Post-market surveillance remains rigorous; between October 2017 and April 2024, the U.S. VAERS database received 66,849 adverse event reports for the recombinant zoster vaccine. Further north, Canada continues its vaccination efforts, with Ontario extending its publicly funded program for certain cohorts through December 31, 2024. In Quebec, approximately 5,000 doses of Shingrix were administered in the first quarter of 2024 under its public program. AIM Vaccine also received U.S. FDA clinical trial approval for its mRNA shingles vaccine on March 23, 2025.

Europe's Strategic Expansion of Publicly Funded Shingles Vaccination Programs

Europe's shingles vaccine market is characterized by the systematic expansion of national immunization programs, driving significant uptake. In the United Kingdom, NHS England is expanding its Shingrix program, making an additional 1 million people eligible for vaccination in the 2024/2025 fiscal year. Spain's regions are also accelerating their efforts; Andalusia vaccinated 27,596 people in the six months following May 2024. GSK is bolstering its European manufacturing capabilities with an investment of over 250 million euros in a new facility in Wavre, Belgium, which is expected to be operational in 2027.

Regulatory and research activities remain strong across the regional shingles vaccine market. In Germany, a new 9,000-square-meter antigen production space is being added to GSK's Marburg site. Clinical research is active, with a GSK-led study analyzing the health records of approximately 1.4 million people in the UK for a potential link between Shingrix and reduced dementia risk. In Ireland, the Health Information and Quality Authority recommended the introduction of a shingles vaccination program for adults aged 65 and older in February 2024. In Italy, the region of Lombardy has allocated funds for over 100,000 doses of the shingles vaccine for its 2024 public health campaign.

Asia Pacific's Emergence as a Pivotal Growth Engine for Shingles Vaccines

The Asia Pacific region is rapidly transforming into a critical growth hub for the shingles vaccine market, led by major strategic initiatives. In China, GSK’s partnership with Zhifei aims to increase the number of Shingrix vaccination points from around 9,000 to over 30,000. Zhifei has agreed to purchase volumes of Shingrix valued at a potential £2.3 billion to GSK through 2029. In a significant regulatory milestone, AIM Vaccine received clinical trial approval for its mRNA shingles vaccine from China's National Medical Products Administration in May 2025.

Australia's National Immunisation Program has seen remarkable success, administering approximately 1.25 million Shingrix doses in its first six months ending April 30, 2024. Data from New South Wales alone shows 384,208 doses were administered between November 2023 and April 2024. Japan is set to launch its national immunization program for shingles in April 2025, initially targeting its 65-year-old population. In South Korea, Shingrix received approval in 2024 for adults aged 18 and older at increased risk. In Thailand, the price per dose for the Shingrix vaccine is 6,300 THB, reflecting private market dynamics in the region.

Strategic Investments and Funding Propel Shingles Vaccine Market Innovation Forward

• Curevo Vaccine Secures Funding (January 2024): Curevo Vaccine announced it had secured sufficient funding to advance its non-mRNA, adjuvanted subunit shingles vaccine candidate, amezosvatein (CRV-101), into a pivotal Phase 3 clinical trial.
• GSK Invests in Belgian Facility (February 2024): GSK announced an investment of over 250 million euros ($273 million) to construct a new, fully digitized vaccine manufacturing facility in Wavre, Belgium, to support its growing vaccine portfolio.
• Pennsylvania Proposes Funding for GSK Site (May 2024): Governor Josh Shapiro announced a proposal for a $1.2 million grant from the Pennsylvania First program to support GSK's planned $800 million expansion of its vaccine manufacturing facility in Marietta.
• GSK Completes Acquisition of Aiolos Bio (February 2024): GSK finalized its acquisition of Aiolos Bio for a $1 billion upfront payment, strengthening its respiratory pipeline, which complements its infectious disease and vaccine divisions.
• Moderna Secures Funding for mRNA Platform (January 2024): Moderna entered a strategic collaboration with The Bill & Melinda Gates Foundation, which provided funding to advance the development of mRNA-based antibody therapeutics, a technology platform relevant to future vaccine development.
• BioNTech Acquires InstaDeep (January 2024): BioNTech, Pfizer's partner on an mRNA shingles vaccine, completed its acquisition of AI company InstaDeep for approximately £562 million to enhance its drug discovery and manufacturing processes in the shingles vaccine market.
• Grifols Invests in Vaccine-Related Plasma Centers (April 2024): Grifols announced a plan to invest approximately $300 million to open 25 to 30 new plasma donation centers in 2024, supporting the supply chain for plasma-derived medicines and immunoglobulins.
• Pfizer Ventures Invests in Biotech (May 2024): Pfizer's venture arm participated in a funding round for a biotech company focused on novel immunology platforms, reflecting ongoing investment in technologies that could inform future vaccine development.
• Zhifei Commits to Purchase Agreement (January 2024): As part of its extended partnership with GSK, Chongqing Zhifei Biological Products committed to a purchase agreement for Shingrix potentially totaling £2.3 billion over three years.
• Sanofi Ventures Co-leads Investment (February 2024): Sanofi's venture capital arm co-led a significant investment round in a company developing next-generation biologics, showcasing major pharmaceutical players' continued investment in innovative therapeutic platforms.

Top Companies in the Shingles Vaccine Market

• Bharat Biotech
• BioNTech
• CanSinoBIO
• Changchun BCHT Biotech
• Curevo Inc.
• Daiichi Sankyo
• GeneOne Life Science
• Geneone Life Science
• Green Cross Corp
• GSK plc
• Jiangsu Recbio Technology
• Johnson & Johnson
• Merck & Co., Inc.
• Moderna
• Novavax
• Pfizer Inc.
• Sinovac
• SK bioscience
• Vaccitech
• Other Prominent Players

Market Segmentation Overview

By Product

• Shingrix
• Zostavax
• SkyZoster

By Vaccine Type

• Recombinant Vaccine
• Live attenuated Vaccine

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America